Last reviewed · How we verify

NCT05695651

Association of Triglyceride Glucose Index and HOMA IR as Predictors of Vascular Complications of DM Type 2

Status unknown Last updated 25 January 2023
What this trial tests

trial testing triglyceride glucose index and HOMA IR in Type 2 Diabetes Mellitus in 56 participants. Status unknown.

Timeline
7 February 2023
Primary endpoint
7 January 2025
7 March 2025

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment56
Start date7 February 2023
Primary completion7 January 2025
Estimated completion7 March 2025

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

19 and older, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Explore the association between Triglyceride glucose index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes. * Which shows better performance for assessing insulin resistance Triglyceride glucose index or HOMA-IR in clinical practice regardless of diabetes status

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05695651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing